Stockscreener 앱 받기
225.25
0.60%
-1.37
전일 마감가:
$226.62
열려 있는:
$226.62
하루 거래량:
680.31K
Relative Volume:
0.87
시가총액:
$14.82B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
25.39
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
-1.74%
1개월 성능:
-9.06%
6개월 성능:
-7.29%
1년 성능:
+8.80%
1일 변동 폭
$223.78
$226.76
1주일 범위
$222.00
$234.01
52주 변동 폭
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
225.25 | 14.82B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-15 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2026-08-27 | 개시 | H.C. Wainwright | Buy |
| 2026-08-19 | 개시 | BMO Capital Markets | Outperform |
| 2026-05-19 | 개시 | Citigroup | Buy |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
Ascendis Pharma (NasdaqGS:ASND) Stock Price - Simply Wall Street
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - finance.yahoo.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis Announces Planned $400 Million Share Repurchase Program - GlobeNewswire
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com UK
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - investing.com
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - Investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com Canada
BMO reiterates Ascendis Pharma stock rating on infant trial data - Investing.com
Ascendis Pharma SVP Mads Bodenhoff Exercises Warrants and Sells 3,000 Shares on September 8, 2026 - Kalkine Media
Early infant trial hints at spine and growth gains, Ascendis Pharma (NASDAQ: ASND) says - Stock Titan
Ascendis Pharma SVP & Pao Sold Shares Worth Over $810K - TradingView
Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - Stock Titan
Ascendis Pharma (NASDAQ: ASND) prices new employee warrants at $270.09 - Stock Titan
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 - GlobeNewswire
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - GlobeNewswire
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) director sells 236 shares in open-market trade - Stock Titan
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ascendis Pharma A S 주식 (ASND) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO |
Sep 08 '26 |
Sale |
270.19 |
3,000 |
810,570 |
0 |
| Bodenhoff Mads | Officer |
Sep 08 '26 |
Proposed Sale |
270.19 |
3,000 |
810,563 |
0 |
| HOLTUG LARS | Director |
Sep 02 '26 |
Sale |
264.13 |
236 |
62,335 |
4,000 |
| HOLTUG LARS | Director |
Sep 02 '26 |
Proposed Sale |
264.13 |
236 |
62,335 |
0 |
| BIENAIME JEAN JACQUES | Director |
Aug 14 '26 |
Buy |
246.33 |
2,000 |
492,654 |
2,900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
Jun 02 '26 |
Buy |
219.00 |
100 |
21,900 |
4,367 |
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
0.95%
0.27%
자본화:
|
볼륨(24시간):